96 Views | 45 Downloads
Cristina Diaz-de-Heredia, Email: crdiaz@vhebron.net
MW provided content of critical importance, drafted the manuscript, and approved the final version. MQ, MB, TS, HB, and AL provided content of critical importance, revised the manuscript, and approved the final version. CD-d-H coordinated the writing process, provided content and structure of critical importance, revised the manuscript, and approved the final version. All authors contributed to the article and approved the submitted version.
Editorial support in the preparation of this manuscript was provided by Hannah Bridges of HB Health Comms Limited.
CD-d-H has acted as a consultant and speaker for and has received travel expenses from Novartis. MW has acted as a consultant for and has received travel expenses from Novartis. MW also received travel expenses from Mallinckrodt Pharmaceuticals. MQ received honoraria from Mesoblasts, Medexus, Jazz Pharmaceuticals, and Novartis. HB owns IP and receives royalties and licencing fees from Medac for an MSC product for aGvHD which he co-invented. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
This study received funding from the St. Anna Children's Cancer Research Institute, Vienna, Austria. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.
© 2022 Wölfl, Qayed, Benitez Carabante, Sykora, Bonig, Lawitschka and Diaz-de-Heredia.